Portal de investigación
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients with Primary Progressive Multiple Sclerosis.
Datos básicos
Documentos
- No hay documentos
Grupos
Financiadores - Promotores
ZENAS BIOPHARMA (USA) LLC
Cita
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients with Primary Progressive Multiple Sclerosis. (ZB020-03-001). ZENAS BIOPHARMA (USA) LLC. 2026IP:FRANCISCO CARLOS PÉREZ MIRALLES.